Last updated: July 11, 2026

Application No. 19/570,115

Untitled Application

Unknown

Filed

Priority

May 02, 2011 — provisional 61/481,522 +7 more

Examiner

HADDAD, MAHER M

Art Unit

Tech Center

Takeda Pharmaceutical Company Limited

Assignee

Takeda Pharmaceutical Company Limited

OA Round

1 (Non-Final)

This examiner grants 50% of cases after interview

— +54.2% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 1048 resolved cases, 2023–2026

Examiner Intelligence

HADDAD, MAHER M View full profile →

Grants 50% of resolved cases

Career Allowance Rate

529 granted / 1048 resolved

-9.5% vs TC avg

Strong +54% interview lift

Without

With

+54.2%

Interview Lift

resolved cases with interview

Typical timeline

3y 0m

Avg Prosecution

56 currently pending

Career history

1108

Total Applications

across all art units

Statute-Specific Performance

§101

0.7%

-39.3% vs TC avg

§103

45.9%

+5.9% vs TC avg

§102

13.1%

-26.9% vs TC avg

§112

17.5%

-22.5% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1048 resolved cases

Prosecution Timeline

Jul 07, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/654,538

Patent 12668630

HUMAN ANTI-SEMAPHORIN 4D ANTIBODY

2y 1m to grant Granted Jun 30, 2026

17/852,474

Patent 12662527

IMPROVED SERUM ALBUMIN BINDING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS

3y 12m to grant Granted Jun 23, 2026

15/555,442

Patent 12655197

INTEGRIN-TARGETING PROTEIN AND METHODS OF USE THEREOF

8y 9m to grant Granted Jun 16, 2026

17/441,656

Patent 12655228

MATERIALS AND METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE

4y 8m to grant Granted Jun 16, 2026

18/269,018

Patent 12649787

METHODS AND COMPOSITIONS RELATING TO ANTI-MFSD2A ANTIBODIES

2y 11m to grant Granted Jun 09, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

50%

Grant Probability

99%

With Interview (+54.2%)

3y 0m

Median Time to Grant

Low

PTA Risk

Based on 1048 resolved cases by this examiner. Grant probability derived from career allowance rate.